Khalil Saleh

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 15

Top Topics

Advanced Non Small Cell Lung Cancer

Metastatic Colorectal Cancer

Endoscopic Submucosal Dissection

Top Venues

Future oncology (London, England)

Pharmacogenomics

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca Ibrahim, Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine, Axel Le Cesne
Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer. Future oncology (London, England) 20 (2) (2024)
Rebecca Ibrahim, Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine, Axel Le Cesne
Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer. Future oncology (London, England) 20 (2) (2024)
Rebecca Ibrahim, Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine, Axel Le Cesne
Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer. Future oncology (London, England) (2024)
Rebecca Ibrahim, Claude Chahine, Tony Felefly, Nadine Khalife, Khalil Saleh
The CLIP1 - LTK fusion: A new oncogenic driver in non-small-cell lung cancer? Future oncology (London, England) (2023)
Rebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury, Nadine Khalife, Axel Lecesne
KRAS G12C mutation in metastatic colorectal cancer: a new target. Future oncology (London, England) (2023)
Rita Khoury, Claude Chahine, Rebecca Ibrahim, Nadine Khalife, Mohammad Saleh, Khalil Saleh
Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma. Future oncology (London, England) (2023)
Khalil Saleh, Ahmadreza Arbab, David Ghez, Camille Bigenwald, Sophie Cotteret, Christophe Marzac, Florence Pasquier, Sylvain Pilorge, Véronique Saada, Véronique Vergé, Vincent Ribrag, Cristina Castilla-Llorente
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation. Immunotherapy (2023)
Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie, Nadine Khalife
Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma? Future oncology (London, England) 18 (5) (2022)
Nadine Khalife, Manal Kordahi, Tony Felefly, Khalil Saleh
Cemiplimab: a new option for the treatment of non-small-cell lung cancer. Future oncology (London, England) 17 (20) (2021)
Khalil Saleh, Manal Kordahi, Tony Felefly, Nadine Khalife
Pembrolizumab: a new standard of care in metastatic colorectal cancer. Immunotherapy 13 (15) (2021)
Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie, Nadine Khalife
KRAS-targeted therapies in advanced solid cancers: drug the undruggable? Pharmacogenomics 22 (10) (2021)
Nadine Khalife, Claude Chahine, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie, Khalil Saleh
Urothelial carcinoma in the era of immune checkpoint inhibitors. Immunotherapy 13 (11) (2021)
Khalil Saleh, Nadine Khalife, Tony Felefly
RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm. Future oncology (London, England) 17 (12) (2021)
Khalil Saleh, Claude Chahine, Nadine Khalife
Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia. Future oncology (London, England) 17 (11) (2021)
Khalil Saleh, Tony Felefly, Nadine Khalife, Hampig Raphael Kourie
Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors. Pharmacogenomics 22 (5) (2021)